Year in Review: Myeloproliferative Neoplasms

Posted on February 10th, 2016 by

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively impacting both disease burden and quality of life. The identification of certain gene conditions that contribute to MPNs has led to improvements in diagnosis and stratifying risk. Ongoing trials will further define the role of JAK inhibitors in MPNs as well as evaluate combination therapies and new targeted therapies.

CancerConnect News coverage of advances in the management of MPNs included the following key developments:

Polycythemia Vera News

Myelofibrosis News

Essential Thrombocythemia


MPN Side Effect News

2015 Presentations


Click here for CURRENT MPN NEWS


Learning More About Myeloproliferative Neoplasms

  • Sign up for monthly MPN newsletters here.
  • Join the CancerConnect online support group to join ongoing discussions with other individuals affected by PV, ET and myelofibrosis here.
  • Follow CancerConnect on Facebookand Twitter.

Copyright © 2016 CancerConnect. All Rights Reserved.

Tags: essential thrombocythemia, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, research, review

You must be logged-in to the site to post a comment.